THURSDAY, June 12, 2025 (HealthDay News) — A newly approved shot could soon help protect babies from respiratory syncytial ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year ...

The long-acting monoclonal antibody is designed to provide "rapid and durable protection" through 5 months -- the typical ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

Tiziana (TLSA) is showing groundbreaking advancements in Alzheimer's & MS treatments with foralumab. Key trials & market ...

The protein language model is trained solely on paired human antibody sequences with scalable applications in antibody ...

Recent innovations across the multiple ADC components, such as enhanced antibody-targeting to the tumors, better linker ...

Study reveals the advantages and pitfalls of adding a TKI to a monoclonal antibody after chemoradiation for non-small cell ...

After dropping its only clinical-stage candidate last month, ADC Therapeutics is shutting down a U.K. research site and ...

The Serum Institute of India collaborates with the Drugs for Neglected Diseases initiative to develop a monoclonal antibody ...